Rajesh Parekh - GALAPAGOS Non-Executive Chairman of the Board

GLPGF -- USA Stock  

USD 185.00  0.00  0.00%

  Chairman
Dr. Rajesh B. Parekh was NonExecutive Chairman of the Board of Galapagos NV since July 2004. He is also Chairman of the Company Nomination and Remuneration Committee. He is a General Partner at Advent Life Sciences LLP, which he joined in 2006. During an academic career at Oxford University, he cofounded Oxford GlycoSciences PLC, where he served as Chief Scientific Officer and Chief Executive Officer from 1988 until its sale to Celltech Group PLC in 2003. He has founded or served on the boards of several life sciences companies in the United States and Europe including Celldex Therapeutics, Inc. Avila Therapeutics, Inc. EUSA Pharma Limited Thiakis Limited and Amsterdam Molecular Therapeutics Holding N.V. . Dr. Parekh currently serves as a member of the board of directors of Advent Venture Partners Advent Life Sciences LLP Aleta Inc. Arrakis, Inc. Aura Inc. Artax Inc. Capella BioSciences Ltd. Cellnovo Limited EnCipher Limited Itara Limited Levicept Limited Macrolide Pharmaceuticals, Inc. PE Limited and Project Paradise Limited. He is also a member of the supervisory board of the Novartis Venture Fund. During the past five years, he served as a member of the board of directors of Biocartis NV, 4Antibody AG, NeRRe Therapeutics Limited, F2G Limited, LuxFold S.A., CoCo Therapeutics Limited. He received his MA in Biochemistry and DPhil in Molecular Medicine from the University of Oxford, where he was a Senior Research Fellow and Professor.
Age: 57  Chairman Since 2004      
32 1 534 29 00  http://www.glpg.com

Management Efficiency

The company has return on total asset (ROA) of 6.84 % which means that it generated profit of $6.84 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 15.06 % meaning that it generated $15.06 on every $100 dollars invested by stockholders.

Similar Executives

Showing few of many executives

CHAIRMAN Since

Art LevinsonApple
2011
Robert MatschullatVisa
2019
Yun MaAlibaba Group Holding Limited
2013
John ThompsonMicrosoft Corporation
2014
Charles MungerBerkshire Hathaway Inc New
1978
Alfred KellyVisa
2019
Ajit JainBerkshire Hathaway Inc New
2018
Ellen RicheyVisa
2014
Joseph TsaiAlibaba Group Holding Limited
2013
Eric SchmidtAlphabet
2018
Valentino SyVisa
2005
Arthur LevinsonApple
2011
Vasant PrabhuVisa
2019
Jeffrey BezosAmazon Com
2000
Mark ZuckerbergFacebook
2012
Gregory AbelBerkshire Hathaway Inc New
2018
Warren BuffettBerkshire Hathaway Inc New
1970

Entity Summary

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. The company was founded in 1999 and is headquartered in Mechelen, Belgium. GALAPAGOS is traded on BATS Exchange in USA.GALAPAGOS NV [GLPGF] is traded as part of a regulated electronic over-the-counter service offered by the NASD.

GALAPAGOS NV Leadership Team

Rajesh Parekh, Non-Executive Chairman of the Board
Andre Hoekema, Sr. VP of Corporate Devel.
Katrine Bosley, Independent Non-Executive Director
Walid AbiSaab, Member of the Executive Committee, Chief Medical Officer
Howard Rowe, Non-Executive Independent Director
Bob Rajan, Non-Executive Independent Director
Harrold Barlingen, Non-Executive Director
Raj Parekh, Non-Executive Chairman of the Board
Elizabeth Goodwin, VP Corporate Communications & Investor Relations
Mary Kerr, Non-Executive Independent Director
Piet Wigerinck, Chief Scientific Officer
Bart Filius, CFO
Christine Mummery, Non-Executive Independent Director
Werner Cautreels, Non-Executive Independent Director
Onno Stolpe, Co-Founder, CEO, Managing Director and Executive Director

Stock Performance Indicators

Current Sentiment - GLPGF

GALAPAGOS NV Investor Sentiment

Macroaxis portfolio users are indifferent in their judgment towards investing in GALAPAGOS NV. What is your judgment towards investing in GALAPAGOS NV? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish
Skip

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please also check Risk vs Return Analysis. Please also try Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Search macroaxis.com